

SPC Number	Owner of Certificate	Patent Title	Product	Active Ingredients	Date of Issue	Date of Expiry	MT Number	EP Number	Authorisation Number	PEC Number	PEC Expiry Date
001/2003	ICOS Corporation 22021 20th Avenue SE Bothell Washington 98021 / US	Tetracyclic derivatives, process of preparation and use	Cialis		REJECTED		1201	0			
002/2004		Tetracyclic derivatives, process of preparation and use			REFUSED		1201	0			
003/2004	Warner-Lambert Company LLC 201 Tabor Road, Morris Plains New Jersey 07950 / US	[R-(R*R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID,ITS LACTONE FORM AND SALTS THEREOF	LIPITOR™ - ATROVASTATIN		REFUSED		1380	0	DE 38365.00/01/0 2/03		
004/2004	Warner-Lambert Company LLC 201 Tabor Road, Morris Plains New Jersey 07950 / US	LACTAM FREE CYCLIC AMINO ACIDS	Neurontin	Neurontin	REFUSED		1499	0	DE PL/0018/0202/ 0203		
005/2004	Otsuka Pharmaceutical Co., Ltd., 2-9, Kanda-Tsukasacho Chiyoda-ku Tokyo / JP	LOW HYGROSCOPIC ARIPIRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF	Lyrica-Pregabalin	Lyrica-Pregabalin	REJECTED		1763	0	EU-D/202279		
006/2004	Warner-Lambert Company LLC 201 Tabor Road, Morris Plains New Jersey 07950 / US	Asymmetric synthesis of pregabalin	Lyrica-Pregabalin	Lyrica-Pregabalin	REJECTED		1539	0	EU/1/04/279		
007/2007	Pfizer Products Inc. Eastern Point Road Groton Connecticut 06340 / US	POLYMORPHS OF A CRYSTALLINE AZOBICYCLO(2,2,2) OCTAN-3-AMINE CITRATE AND THEIR PHARMACEUTICAL COMPOSITIONS	Cerenia - Maropitant	Cerenia - Maropitant	5th December 2007	18th September 2021	1455	0	EU/2/06/062		
008/2008	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	TROPANE DERIVATIVES USEFUL IN THERAPY	Celsentri - maraviroc	Celsentri - maraviroc	17th July 2008	20th September 2022	1578	0	EU/1/07/418	PEC 3/2020	20/03/2023
009/2009	AstraZeneca AB 151 85 Södertälje / SE	Chemical process			25th August 2009	14th October 2023	2227	0	MA044/01502 - 03-04	PEC 8/2021	14/04/2024
010/2011	UCB Pharma GmbH Alfred-Nobel-Strasse 10 40789 Monheim / DE	STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE			WITHDRAWN		452	2029134			
011/2013	Eisai R&D Management Co. Ltd. 6-10, Koishikawa 4-chome, Bunkyo-ku Tokyo 112-8088 / JP	CRYSTALS OF 1,2-DIHYDROPYRIDINE COMPOUND AND THEIR PRODUCTION PROCESS	Fycompa-Perampanel	Fycompa-Perampanel	4th December 2013	23rd July 2027	2877	0			

012/2013	Almirall, S.A. Ronda General Mitre 151 08022 Barcelona / ES	PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3-PHENOXYPROPYL)-1 - AZONIABICYCLO[2.2.2]OCTANE BROMIDE	Eklira Genuair-aclidinium bromide	aclidinium bromide	4th December 2013	25th July 2027	30031	2044067			
013/2013	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ / UK	INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES AND METHODS FOR THEIR USE	Inlyta-Axitinib	Inlyta-Axitinib	4th December 2013	30th June 2025	1473	0	EU/1/12/777		
014/2013	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ / UK	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors	XALKORI - crizotinib	XALKORI - crizotinib	4th December 2013	23rd October 2027	2948	0			
015/2013	AstraZeneca AB SE- 151 85 Sodertalje / SE	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD	Forxiga-dapagliflozin	Forxiga-dapagliflozin	31st July 2019	14th November 2027	1907	0	C (2012) 8378		
016/2013	The Trustees of The University of Pennsylvania Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia, PA 19104 / US	STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES	Amyvid - Florbetapir (18F)	Amyvid - Florbetapir (18F)	4th December 2013	17th January 2028	30646	1999109	EU/1/12/805		
017/2013	Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE TREATMENT OF SYSTEMIC DISEASES IN CATS	Semintra-Telmisartan	Semintra-Telmisartan	7th February 2014	13th February 2028	31279	2086535	EU/2/12/146/01		
018/2013	Japan Tobacco Inc 2-1, Toranomon 2-chome Minato-ku Tokyo 105-8422 / JP	STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND	Stribild	elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil	7th February 2014	27th May 2028	2785	0	EU/1/13/830/01-002	PEC 10/2022	27/11/2028
019/2014	ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm / DE	METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF	Lonquex - lipegfilgrastim	Lonquex - lipegfilgrastim	15th July 2014	25th July 2028	31122	2144923	EU/1/13/856		
020/2014	Novartis AG CH-4002 Basel / CH  Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH 12 5AB / UK	ORGANIC COMPOUNDS	Ultibro Breezhaler	Ultibro Breezhaler - Indacaterol maleate/glycopyrronium bromide	11th September 2014	19th September 2028	3071	0	EU/1/13/862		
021/2014	Mitsubishi Tanabe Pharma Corporation 3-2-10, Dosho-machi Chuo-ku, Osaka-shi Osaka 541-8505 / JP	CRYSTALLINE FORM OF 1- (β-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 - FLUOROPHENYL) -2- THIENYLMETHYL]BENZENE HEMIHYDRATE	Invokana - canagliflozin	Canagliflozin hemihydrate	5th September 2015	19th November 2028	32142	2102224	EU/1/13/884		

022/2014	Biogen MA Inc. 250 Binney Street Cambridge, MA 02142 / US	Compositions and Uses for Treating Multiple Sclerosis	Tecfidera - Dimethyl fumarate	Dimethyl fumarate	On hold		31523	2137537	EU/1/13/837		
023/2014	AstraZeneca AB SE- 151 85 Sodertalje / SE	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD	Xigduo	A combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as protected by basic patent 1907	3rd December 2014	13th May 2028	1907	1506211	EU/1/13/900		
024/2014	Janssen Pharmaceutica NV. Turnhoutseweg 30 2340 Beerse / BE	NOVEL MYCOBACTERIAL INHIBITORS	Sirturo	Bedaquiline, or a pharmaceutically acceptable acid or base addition of salt thereof, including bedaquiline fumarate	3rd December 2014	23rd July 2028	1948	0	EU/1/13/901		
025/2014	Glaxo Group Limited 980 West Road Brentford, Middlesex TW8 9GS / GB	MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS	INCRUSE	umeclidinium bromide	5th September 2015	28th April 2029	2735	0	EU/1/14/922		
026/2014							3660	0			
027/2014	MEDIVIR AB Lunastigen 7 141 44 Huddinge / SE	HCV NS-3 SERINE PROTEASE INHIBITORS	Olysio	Simeprevir, or a pharmaceutically acceptable salt thereof, including simeprevir sodium	5th September 2015	14th May 2029	2606	0	EU/1/14/924		
028/2014	Japan Tobacco Inc. 2-1, Toranomom 4-chome Minato-ku Tokyo 105-8422 / JP	PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF	Mekinist	Trametinib, optionally in the form of a pharmaceutically acceptable salt, hydrate or solvate thereof	5th September 2015	2nd July 2029	2825	0	EU/1/14/931		
029/2014	Gilead Pharmasset LLC Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 / US  Gilead Sciences International LTD. Cambridge CB21 6GT / UK	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS	Sovaldi (sofosbuvir)	Sovaldi (sofosbuvir)	7th December 2015	17th January 2029	32301	2203462	EU/1/13/894	PEC 5/2021	17/07/2029
030/2015	Bristol-Myers Squibb Holdings Ireland Hinterbergstrasse 16 6312 Steinhausen / CH	HEPATITIS C VIRUS INHIBITORS	Daklinza	daclatasvir and pharmaceutically acceptable salts thereof, especially daclatasvir dihydrochloride	7th December 2015	22nd August 2029	31906	2049522	EU/1/14/939/0 01-004		
031/2015	F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH	ANTIBODY FORMULATION	Gazyvaro	Obinutuzumab and all variants thereof	7th December 2015	23rd July 2029	32047	2234600	EU/1/14/937		

032/2015	AbbVie Bahamas Ltd. Sassoon House Shirley Street & Victoria Avenue New Providence Nassau Bahamas	ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF	Exviera - dasabuvir	dasabuvir, in all forms protected by the patent	7th December 2015	15th January 2030	30472	2203431	EU/1/14/983		
033/2015	AbbVie Bahamas Ltd. Sassoon House Shirley Street & Victoria Avenue New Providence Nassau Bahamas	Hepatitis C virus inhibitors	Viekirax - ombitasvir / paritaprevir / ritonavir	Ombitasvir, in any form protected by the basic patent	16th February 2016	15th January 2030	31200	2368890			
034/2015	Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown, MA 02472 / US4  AbbVie Bahamas Ltd. Sassoon House Shirley Street & Victoria Avenue New Providence, Nassau / BS	MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS	Viekirax - ombitasvir / paritaprevir / ritonavir	Paritaprevir, in any form protected by the basic patent	7th December 2015	15th January 2030	31870	2340029	EU/1/14/982		
035/2015	Kudos Pharmaceuticals Limited 2 Kingdom Street London W2 6BD / GB	POLYMORPHIC FORM OF 4-[3-(4- CYCLOPROPANECARBONYL-PIPERAZINE-1- CARBONYL)-4-FLUORO-BENZYL]-2H- PHTHALAZIN-1-ONE	Lynparza - Olaparib	Olaparib	7th December 2015	16th December 2029	30503	2064189	EU/1/14/959 - 001		
036/2015	CELGENE CORPORATION 86 Morris Avenue Summit, NJ 07901 / US	SOLID FORMS COMPRISING (+)-2-[1-(3- ETHOXY-4-METHOXYPHENYL)-2- METHYLSULFONYLETHYL]-4- ACETYLAMINOISOINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF	Otezla	Apremilast	Suspended	15th January 2030	31984	2276483	EU/1/14/981		
037/2015	Almirall, S.A. Ronda del General Mitre 151 08022 Barcelona / ES	NHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Brimica Genuair - aclidinium bromide / formoterol fumarate dihydrate	A combination of (a) formoterol, optionally in the form of its pharmacologically- compatible acid addition salts, especially formoterol fumarate, and (b) aclidinium in free or pharmaceutically acceptable salt form, especially aclidinium bromide	4th June 2018	21st November 2029	332061	2265257	EU/1/14/963		

038/2015	GALDERMA INTERNATIONAL Tour Europlaza, 20 avenue André Prothin La Défense 4, 92927 La Défense Cedex, PARIS / FR	USE OF INVERMECTINE FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS	Soolantra	Soolantra (active ingredient: Ivermectin for its use in the treatment of rosacea)	29th November 2016	23rd April 2029	2197	0	EU/1/14/961 MA117-01101		
039/2015	EISAI R&D MANAGEMENT CO., LTD. 6-10 Koishikawa 4-chome Bunkyo-ku Tokyo 1128088 / JP	A crystalline form of the salt of 4-(3-chloro- 4- )cyclopropylaminocarbonyl)aminophenoxy)- 7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same	Lenvatinib	Lenvima (active ingredient: lenvatinib)	4th March 2016	27th December 2029	2557	0	EU/1/15/1002/ 001-002		
040/2015	Novartis Europharm Limited Frimley Business Park Camberley GU 16 7SR / UK	COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS	Zykadia - ceritinib	ceritinib or a pharmaceutically acceptable salt thereof	3rd November 2016	8th May 2030	32135	2091918	EU/1/15/999		
041/2015	Novartis AG Lichtstrasse 35 4056 Basel / CH	COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS	Odomzo (sonidegib)	sonidegib or a pharmaceutically acceptable salt, hydrate of solvate thereof	21st May 2018	18th August 2030	31168	2021328	EU/1/15/1030		
042/2015	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS	Stribild	cobicistat or a pharmaceutically acceptable salt thereof	21st May 2018	27th May 2028	32628	2049506	EU/1/13/830	PEC 1/2008	27/11/2028
043/2016	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem / NL	ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1	Keytruda (pembrolizumab)	keytruda (pembrolizumab)	21st May 2018	21st July 2030	31674	2170959	EU/1/15/1024	PEC 9/2021	21/01/2031
044/2016	Gilead Pharmasset LLC 333 Lakeside Drive Foster City, CA 94404 / US	ANTIVIRAL COMPOUNDS	Harvoni (ledipasvir/sofosbuvir)	ledipasvir	21st May 2018	12th May 2030	33371	2430014	EU/1/14/958	PEC 4/2020	18/05/2030
045/2016	GlaxoSmithKline LLC Corporation Service Company 2711 Centreville Road Suite 400 Wilmington, Delaware 19808 / US	METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES	Nucala	mepolizumab	21st May 2018	7th December 2030	32454	2152290	EU/1/15/1043	PEC 2/2018	07/06/2031
046/2016	Novartis AG Lichtstrasse 35 4056 Basel / CH	SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL- 1H-INDOL-3- YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2- PROPENAMIDE	Farydak	panobinostat or a pharmaceutically acceptable salt, or derivative thereof	21st May 2018	1st September 2030	33550	2032531	EU/1/15/1023		
047/2016	Novartis AG Lichtstrasse 35 4056 Basel / CH	ORGANIC COMPOUNDS	Entresto	Sacubitril/valsartan, as sacubitril valsartan sodium salt complex	22nd May 2018	23rd November 2030	3880	0	EU/1/15/1058		
048/2016	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	COMPOSITION FOR TREATING A PULMONARY HYPERTENSION	Volibris	Ambrisentan used in combination treatment with tadalafil	22nd May 2018	25th November 2030	330491	2101777	EU/1/08/451		

049/2016	Alcafleu Management GmbH & Co. KG Lilienthalstrasse 4 12529 Schönefeld OT Waltersdorf / DE  Genzyme Corporation 50 Binney Street Cambridge, MA 02142 / US	TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H	Lemtrada	Alemtuzumab	22nd May 2018	16th September 2028	33767	2066352	EU/1/13/869		
050/2016	Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US	ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)	Repatha - Evolocumab	Evolocumab	15th February 2021	21st July 2030	33727	2215124	EU/1/15/1016	PEC 15/2023	21/01/2031
051/2016	PTC Therapeutics, Inc. 100 Corporate Court, Middlesex Business Center South Plainfield, NJ 07080 / US	CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID	Translarna	ataluren	22nd May 2018	5th August 2029	33740	2076501	EU/1/13/902		
052/2016	Ardea Biosciences, Inc. 4939 Directors Place San Diego CA 92121 / US	NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE	Zurampic - lesinurad	lesurinad or a pharmaceutically acceptable salt thereof	22nd May 2018	22nd February 2031	32063	2217577	EU/1/15/1080		
053/2016	Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US	ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)	Praluent-alirocumab	Alirocumab	WITHDRAWN		33727	2215124	EU/1/15/1031		
054/2016	AbbVie Biotherapeutics Inc. 1500 Seaport Boulevard Redwood City, CA 94063 / US  Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215-5450 / US	METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES	Empliciti	Elotuzumab	5th June 2018	13th May 2031	32372	2068874	EU/1/16/1088		
055/2016							0	0			
056/2016	AbbVie Biotherapeutics Inc. 1500 Seaport Boulevard Redwood City, CA 94063 / US  Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215-5450 / US	METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES	Empliciti	Elotuzumab combined with lenalidomide	5th June 2018	13th May 2031	32372	2068874	EU/1/16/1088		
057/2016							0	0			

058/2016	AbbVie Biotherapeutics Inc. 1500 Seaport Boulevard Redwood City, CA 94063 / US	METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES	Empliciti	Elotuzumab combined with lenalidomide & dexamethasone	5th June 2018	13th May 2031	32372	2068874	EU/1/16/1088		
059/2016	Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215-5450 / US						0	0			
060/2016	Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, NJ 08512 / US	TREATMENT OPTIONS FOR FABRY DISEASE	Galafold	Migalastat or a salt thereof, including the hydrochloride salt	15th June 2018	31st May 2031	33453	2787345	EU/1/15/1082		
061/2016	BIAL - Portela & Ca., S.A. À Av. da Siderurgia Nacional 4745-457 S. Mamede do Coronado / PT	Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime	Ongentys - opicapone	Ongentys opicapone or a pharmaceutically acceptable salt thereof	18th June 2018	28th June 2031	33912	2481410	EU/1/15/1066		
062/2016	Horizon Therapeutics, LLC 150 S. Saunders Rd. Lake Forest IL 60045 / US	METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS	Ravicti	Glycerol phenylbutyrate	15th June 2018	1st December 2030	34065	2330892	EU/1/15/1062		
063/2017	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	Modulators of pharmacokinetic properties of therapeutics	Genvoya	Cobicistat or a pharmaceutically acceptable salt thereof and tenofovir alafenamide or a pharmaceutically acceptable salt thereof, in particular tenofovir alafenamide fumarate	15th June 2018	No longer valid as from 5 July 2022 - basic patent (EP2487166) has been revoked	34208	2487166	EU/1/15/1061		
064/2017	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	Modulators of pharmacokinetic properties of therapeutics	Rezolsta	Cobicistat or a pharmaceutically acceptable salt or solvate thereof and darunavir or a pharmaceutically acceptable salt or solvate thereof, in particular darunavir ethanolate	15th June 2018	No longer valid as from 5 July 2022 - basic patent (EP2487162) has been revoked	34206	2487162	EU/1/14/967		
065/2017	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	Modulators of pharmacokinetic properties of therapeutics	Evotaz	Cobicistat or a pharmaceutically acceptable salt thereof and atazanavir or a pharmaceutically acceptable salt thereof, in particular atazanavir sulfate	15th June 2018	No longer valid as from 5 July 2022 - basic patent (EP2487163) has been revoked	34207	2487163	EU/1/15/1025		
066/2017	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS	Zepatier (grazoprevir)	Grazoprevir or a pharmaceutically acceptable salt thereof	15th June 2018	26th July 2031	30922	2310095	EU/1/16/1119		

067/2017	Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US	INHIBITORS OF HEPATITIS C VIRUS REPLICATION	Zepatier (elbasvir)	Elbasvir or a pharmaceutically salt thereof	20th July 2018	26th July 2031	33383	2410844	EU/1/16/1119		
068/2017	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	SOLID FORMS OF 3-(6-(1-(2,2- DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3- METHYLPYRIDIN-2-YL) BENZOIC ACID	Orkambi	3-{6-[[1-(2,2-difluoro-1,3- benzodioxol-5- yl)cyclopropanecarbonyl]ami no}-3-methylpidin-2- yl}benzoic acid	20th July 2018	24th November 2030	34064	2225230	EU/1/15/1059		
069/2017	Santen SAS 1, rue Pierre Fontaine Bâtiment Genavenir IV 91000 Evry / FR	COMPOSITIONS CONTAINING QUATERNARY AMMONIUM COMPOUNDS	Ikervis	Ciclosporin Anatomical main group: S - Sensory organs Therapeutic subgroup: S01 - Ophthalmologicals Pharmacological subgroup: S01X - Other ophthalmologicals Chemical subgroup: S01XA - Other ophthalmologicals Chemical substance: S01XA18- Ciclosporin	20th July 2018	23rd March 2030	34398	2049079	EU/1/15/990		
070/2017	Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ / GB	2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3- d]PYRIMIDIN-7-ON	IBRANCE - palbociclib - EU/1/16/1147	Palbociclib (optionally in the form of a pharmaceutically acceptable salt, ester, amide or prodrug thereof)	3rd August 2018	20th December 2027	1836	0	EU/1/16/1147		
071/2017	Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 / JP	PROTEASOME INHIBITORS	Ninlaro - ixazomib	Ixazomib and pharmaceutically acceptable salts and esters thereof, such as ixazomib citrat	3rd August 2018	23rd November 2031	30821	2178888	EU/1/16/1094		
072/2017	Kai Pharmaceuticals, Inc. 270 Littlefield Avenue South San Francisco, CA 94080 / US	THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS	Parsabiv	Etelcalcetide, or a salt thereof, including etelcalcetide hydrochloride	3rd August 2018	15th November 2031	34759	2459208	EU/1/16/1142		
073/2017	Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL- SUBSTITUTED BENZENE DERIVATIVE	Glyxambi	1-chloro-4-(β-D- glucopyranos-1-yl)-2-[4-((S)- tetrahydrofuran-3-yloxy)- benzyl]- benzene(empagliflozin) in combination with 1-[(4- methyl-quinazolin-2- yl)methyl]-3-methyl-7-(2- butyn- 1 -yl)-8-(3-(R)-amino- piperidin- 1 -yl)-xanthine (linagliptin) or a pharmace	3rd August 2018	15th November 2031	34782	2187879	EU/1/16/1146/		



074/2017	AbbVie Bahamas Ltd. Sassoon House Shirley Street & Victoria Avenue New Providence, Nassau / BS	APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES	Venclyxto	Venetoclax (Venclyxto)	3rd August 2018	7th December 2031	33429	2435432	EU/1/16/1138		
075/2017	BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, CA 94949 / US	MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN LYSOSOMAL SULFATASE ENZYMES AND USES THEREOF			3rd August 2018	30th April 2029	34199	2245145	EU/1/14/914		
076/2017	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	HIGH AFFINITY HUMAN ANTIBODIES TO PCSK9	Praluent - alirocumab	alirocumab	6th August 2018	25th September 2030	35197	2358756	EU/1/15/1031		
077/2017	Sanofi-Aventis Deutschland GmbH Brüningsstraße 50 65929 Frankfurt am Main / DE	PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN, AND METHIONINE	Suliqua - insulin glargine / lixisenatide	Suliqua	6th August 2018	13th January 2032	32297	2498802	EU/1/16/1157		
078/2017	Chugai Seiyaku Kabushiki Kaisha 5-1, Ukima 5-chome Kita-ku Tokyo 115-8543 / JP	TETRACYCLIC COMPOUND	alectinib	Alectinib or salt or solvate thereof	16th November 2018	20th February 2032	33565	2441753	EU/1/16/1169		
079/2017	Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	ANTICOAGULANT ANTIDOTES	Praxbind - Idarucizumab	Idarucizumab	6th August 2018	24th November 2030	34148	2525812	EU/1/15/1056	PEC 12/2022	24/05/2031
080/2017	Incyte Holdings Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 / US	AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS	Olumiant - baricitinib	Baricitinib	6th August 2018	15th February 2032	34054	2288610	EU/1/16/1170		
081/2017	Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ / GB	Chiral salt resolution	Xeljanz - Tofacitinib	Tofacitinib, optionally in the form of a pharmaceutically acceptable salt, including the citrate salt	23rd August 2018	30th May 2027	1728	0	EU/1/17/1178		
082/2017	E. I. du Pont de Nemours and Company Chestnut Run Plaza 974 Center Road P.O. Box 2915 Wilmington, DE 19805 / US	NAPHTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS	NexGard - afoxolaner	Afoxolaner, or a pharmaceutically acceptable salt thereof	22nd August 2018	13th February 2029	34662	2158188	EU/2/13/159		
083/2017	AbbVie Bahamas Ltd. Sassoon House Shirley Street & Victoria Avenue New Providence, Nassau / BS	An antiviral 1-phenyl-2,5-dibenzimidazol-5- yl-pyrrolidine derivative	Maviret - glecaprevir / pibrentasvir	Maviret pibrentasvir or a pharmaceutically acceptable salt thereof	13th July 2018	28th July 2032	33877	2692346	EU/1/17/1213	PEC 6/2021	28/1/2033

084/2017	Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown, MA 02472 / US	MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS	Maviret	Maviret glecaprevir or a pharmaceutically acceptable salt or ester thereof	13th July 2018	28th July 2032	33648	2618831	EU/1/17/1213	PEC 7/2021	28/1/2033
085/2017	Roche Glycart AG Wagistrasse 18 8952 Schlieren-Zuerich / CH	COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE	Gazyvaro - obinutuzumab	Obinutuzumab in combination with Bendamustine	22nd August 2018	15th June 2031	34633	2464382	EU/1/14/937		
086/2017	Novartis AG Lichtstrasse 35 4056 Basel / CH  Astex Therapeutics Ltd. 436 Cambridge Science Park Milton Road Cambridge CB4 0QA / GB	PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS	Kisqali - ribociclib	Ribociclib or a pharmaceutically acceptable salt thereof	22nd August 2018	24th August 2032	32026	2331547	EU/1/17/1221		
087/2017	REGENERON PHARMACEUTICALS, INC. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR	Kevzara - sarilumab	sarilumab	23rd August 2018	1st June 2032	30593	2041177	EU/1/17/1196		
088/2017	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTO	Dupixent - dupilumab	dupilumab	25th August 2018	28th September 2032	31371	2356151	EU/1/17/1229	PEC 14/2023	28/03/2033
089/2017	F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH	ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION	Tecentriq - atezolizumab	atezolizumab	25th August 2018	25th September 2032	34913	2376535	EU/1/17/1220		
090/2018	Kirin-Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 / US	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	Kyntheum - brodalumab	An isolated antibody or fragment thereof comprising light chain and heavy chain CDR sequences according to EP-B1-2076541 claim 1 (SEQ ID Nos: 224, 225, 226 and 146, 147, 148), wherein the antibody or fragment thereof binds human IL-17 receptor A; especial	7th September 2018	19th July 2032	32793	2076541	EU/1/16/1155		
091/2018					WITHDRAWN		32661	2365988			
092/2018	Chiesi Farmaceutici S.p.A. Via Palermo 26/A 43122 Parma / IT	Combination therapy for COPD	Trimbow - beclometasone / formoterol / glycopyrronium bromide	A combination of glycopyrronium bromide, formoterol or a salt thereof and beclometasone dipropionate	25th August 2018	19th July 2032	32121	2515855	EU/1/17/1208		

093/2018	Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP	PHARMACEUTICAL COMPOSITION	Lixiana - edoxaban	Edoxaban, a pharmaceutically acceptable salt thereof, or a hydrate of any of these, in particular Edoxaban p-toluenesulfonate monohydrate	25th August 2018	23rd June 2030	35512	2140867	EU/1/15/993		
094/2018	Bayer Intellectual Property GmbH Alfred-Nobel-Strasse 10 40789 Monheim / DE	Combination therapy of substituted oxazolidinones	Xarelto - rivaroxaban	Xarelto	23rd August 2018	24th May 2028	34999	2099453	EU/1/08/472		
095/2018	Nippon Shinyaku Co., Ltd. 14, Kisshoin Nishinosho Monguchicho Minami-ku Kyoto-shi Kyoto 607-8217 / JP	Crystals	Uptravi - selexipag	Selexipag, which has the following formula: It has the IUPAC designation "2-{4-[(5,6-diphenylpyrazin-2-yl)amino]butoxy}-N-methanesulfonyl)acetamide"	19th November 2018	19th May 2031	35900	2447254	EU/1/15/1083		
096/2018	MSD Italia S.r.L. Via Vitorchiano 151 CAP 00189 Rome / IT	AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS	Zejula (Niraparib)	Niraparib or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, particularly the tosylate or a hydrate, especially the tosylate monohydrate	25th August 2018	20th November 2032	30300	2109608	EU/1/17/1235		
097/2018	Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK	GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES	Refixia - nonacog beta pegol	nonacog beta pegol	20th November 2018	7th June 2032	35932	2068907	EU/1/17/1193/001-002		
098/2018	Glaxo Group Limited 980 Great West Road Brentford, Middlesex TW8 9GS / GB	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Trelegy Ellipta - fluticasone furoate/umeclidinium/vilanterol	A pharmaceutical combination product comprising a pharmaceutically acceptable salt of umeclidinium (e.g. umeclidinium bromide), vilanterol or a pharmaceutically acceptable salt thereof (e.g. vilanterol trifenate) and fluticasone furoate	22nd November 2018	17th November 2032	35933	2506844	EU/1/17/1236		

099/2018	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOLEDERIVATIVES	Steglatro - ertugliflozin	Ertugliflozin, optionally as a crystal form, particularly as a co-crystal with L-pyroglutamic acid, and specifically as Ertugliflozin L-pyroglutamic acid	22nd November 2018	23rd March 2033	30566	2334687	EU/1/18/1267		
100/2018	Kyowa Hakko Kirin Co., Ltd. 1-6-1, Ohtemachi Chiyoda-ku Tokyo 100-8185 / JP	Anti-FGF23 antibody and pharmaceutical composition comprising the same	CRYSVITA - Burosumab	Burosumab	22nd November 2018	14th February 2033	35350	2502996	EU/1/17/1262		
101/2018	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	POLYCYCLIC-CARBAMOYLPIRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE	Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium	Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide	18th December 2018	25th December 2033	34020	2822954	EU/1/18/1289		
102/2018	GlaxoSmithKline Biologicals SA Rue de l'Institut 89 1330 Rixensart / BE	Vaccine	Shingrix	Varicella Zoster Virus (VZV) glycoprotein E (gE)	18th December 2018	3rd March 2031	3328	0	EU/1/18/1272		
103/2018	VIIV Healthcare Company 251 Little Falls Drive Wilmington, DE 19808 / US	ANTIVIRAL THERAPY	Juluca - dolutegravir / rilpivirine	A combination comprising dolutegravir or a pharmaceutically acceptable salt thereof (e.g. dolutegravir sodium) and rilpivirine or a pharmaceutically acceptable salt thereof (e.g. rilpivirine hydrochloride)	29th January 2019	18th May 2033	36376	2932970	EU/1/18/1282		
104/2018	Kudos Pharmaceuticals Limited 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, CB2 0AA / GB	PHARMACEUTICAL FORMULATION 514	Lynparza - Olaparib	Lynparza - Amorphous olaparib or a salt or solvate thereof, in a solid dispersion	SURRENDERED ON 15/5/2019	15th May 2033	33846	2346495	EU/1/14/959		
105/2018	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE	Rubraca - rucaparib	Rucaparib camsylate	29th January 2019	29th May 2033	34104	2534153	EU/1/17/1250		
106/2018	Vifor (International) Ltd. Rechenstrasse 37 9001 St.Gallen / CH	COMPOSITIONS COMPRISING CROSSLINKED CATION EXCHANGE POLYMERS AND USE IN TREATING HYPERKALEMIA	Veltassa - patiromer	Patiromer sorbitex calcium	25th March 2019	21st July 2032	36456	2957286	EU/1/17/1179		
107/2018	Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US	HUMAN CGRP RECEPTOR BINDING ANTIBODIES	Aimovig - erenumab	Erenumab	25th March 2019	30th July 2033	35226	2379594	EU/1/18/1293		

108/2019	Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US	MODULATION OF TRANSTHYRETIN EXPRESSION	Inotersen	A compound comprising a modified oligonucleotide having a nucleobase sequence consisting of 20 linked nucleosides according to EP B1 2563920 claim 1 (SEQ ID NO: 80), wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked de	25th March 2019	10th July 2033	34488	2563920	EU/1/18/1296		
109/2019	Merck Sharp & Dohme LLC 126 East Lincoln Ave., P.O. Box 2000 Rahway, NJ 07065 / US	ENGINEERED ANTI-IL-23P19 ANTIBODIES	Ilumetri - tildrakizumab	tildrakizumab	25th March 2019	21st February 2033	30751	2059534	EU/1/18/1323		
110/2019	Medimmune Limited Milstein Building Granta Park Cambridge, Cambridgeshire CB21 6GH / GB	TARGETED BINDING AGENTS AGAINST B7- H1	Imfinzi - durvalumab	An antibody that binds to B7- H1 comprising a heavy chain CDR1 amino acid sequence of GFTFSRYWMS, a heavy chain CDR2 amino acid sequence of NIKQDGSEKYYVDSVKG, a heavy chain CD3 amino acid sequence of EGGWFGELAFDY, a light chain CDR1 amino acid sequence of	5th August 2019	25th September 2033	35158	2504364	EU/1/18/1322		
111/2019	The Trustees of The University of Pennsylvania Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia PA 19104-6283 / US	USE OF CHIMERIC ANTIGEN RECEPTOR- MODIFIED T CELLS TO TREAT CANCER	Kymriah - tisagenlecleucel	tisagenlecleucel	21st August 2019	27th August 2033	35258	2649086	EU/1/18/1297		
112/2019	The Trustees of The University of Pennsylvania Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia PA 19104-6283 / US	USE OF CHIMERIC ANTIGEN RECEPTOR- MODIFIED T CELLS TO TREAT CANCER	Kymriah - tisagenlecleucel	tisagenlecleucel	WITHDRAWN		36501	3214091	EU/1/18/1297		

113/2019	Ardea Biosciences, Inc. 9390 Towne Centre Drive San Diego CA 92121 / US	TREATMENT OF GOUT AND HYPERURICEMIA	Allopurinol/Lesinurad	The Duzallo product includes the active ingredients allopurinol and lesinurad or a pharmaceutically acceptable salt or salts thereof	13th May 2019	27th August 2033	35824	2582683	EU/1/18/1300		
114/2019	Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US	Compositions and methods for inhibiting expression of transthyretin	Onpattro - patisiran	Onpattro (patisiran)	13th May 2019	29th August 2033	35371	2937418	EU/1/18/1320		
115/2019	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	PROTEIN KINASE INHIBITORS	Verzenio - abemaciclib	abemaciclib	13th May 2019	1st October 2033	31381	2379528	EU/1/18/1307		
116/2019	Tetraphase Pharmaceuticals, Inc. 480 Arsenal Street, Suite 110 Watertown, MA 02472 / US	C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS	Xerava - Eravacycline	Eravacycline or a pharmaceutically acceptable salt thereof	31st May 2019	24th September 2033	31386	2323972	EU/1/18/1312		
117/2019	Array BioPharma, Inc. 3200 Walnut Street Boulder CO 80301 / US	Compounds and Compositions as Protein Kinase Inhibitors	Mektovi - binimetinib	Binimetinib in combination with encorafenib, each optionally in the form of a pharmaceutically acceptable salt or solvate	01st September 2020	24th September 2033	34814	2727918	EU/1/18/1315		
118/2019	Array BioPharma, Inc. 3200 Walnut Street Boulder CO 80301 / US	COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS	Braftovi - encorafenib	Encorafenib or a pharmaceutically acceptable salt or solvate thereof	23rd June 2020	24th September 2033	31902	2470526	EU/1/18/1314		
119/2019	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	CGRP ANTIBODIES	Emgality - galcanezumab	galcanezumab	31st May 2019	16th November 2033	35641	2579894	EU/1/18/1330		
120/2019	ZS Pharma, Inc 508 Wrangler Dr., Suite 100 Coppell, TX 75019-7609 / US	USE OF A ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA	Lokelma - sodium zirconium cyclosilicate	sodium zirconium cyclosilicate	1st July 2019	26th March 2033	36657	2673237	EU/1/17/1173		
121/2019	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS	Symkevi - tezacaftor/ivacaftor	1-(2,2-difluoro-2H-1,3- benzodioxol-5-yl)-N-{1-[(2R)- 2,3-dihydroxypropyl]-6- fluoro-2-(1-hydroxy-2- methylpropan-2-yl)-1H-indol- 5-yl}cyclopropane-1- carboxamide	24th June 2019	6th November 2033	32832	2365972	EU/1/18/1306		

122/2019	Dyax Corp. 300 Shire Way Lexington, MA 02421 / US	PLASMA KALLIKREIN BINDING PROTEINS	Takhzyro - lanadelumab	An antibody comprising a VH sequence of EVQLLESGGGLVQPGGSLRLSC AASGFTFSHYIMMWVRQAPG KGLEWVSGIYSSGGITVYADSV KGRFTISRDNKNTLYLQMNSL RAEDTAVYYCAYRRIGVPRRDE FDIWGQGTMTVSS and a VL sequence of DIQMTQSPSTLSASVGDRVIT CRASQSISSWLAWYQQKPGKA PKLLIYKASTLESGVPSRFSGSGS GTEF	24th June 2019	26th November 2033	36535	2521568	EU/1/18/1340		
123/2019	Ardenia Investments Ltd. First Floor 45 Welbeck Street London, Greater London W1G 8DZ / GB	DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES	Apealea - paclitaxel	paclitaxel micellar	1st July 2019	22nd November 2033	35273	2231189	EU/1/18/1292		
124/2019	Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi Osaka Japan	PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS	Brigatinib	Brigatinib, or a pharmaceutically acceptable salt thereof	1st July 2019	26th November 2033	35531	2300013	EU/1/18/1264		
125/2019	Merck Canada Inc. 16711 Trans-Canada Highway Kirkland QC H9H 3L1 / CA	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	Pifeltro - doravirine	Doravirine or a pharmaceutically acceptable salt thereof	17th July 2019	27th November 2033	32413	2552902	EU/1/18/1332		
126/2019	Merck Canada Inc. 16711 Trans-Canada Highway Kirkland QC H9H 3L1 / CA	PHARMACEUTICAL COMPOSITION COMPRISING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	DELSTRIGO (doravirine / lamivudine/tenofovir disoproxil)	Doravirine or a pharmaceutically acceptable salt thereof in combination with lamivudine or a pharmaceutically acceptable salt thereof in combination with tenofovir or an ester thereof, in particular a disoproxil ester or a pharmaceutically acceptable salt	17th July 2019	26th November 2033	34053	2924034	EU/1/18/1333		
127/2019	The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	Erleada - apalutamide	apalutamide or a pharmaceutically acceptable salt thereof	1st July 2019	27th March 2032	31608	2368550	EU/1/18/1342		

128/2019	Incyte Holdings Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 / US	USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3- D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE	Ruxolitinib	A salt selected from the group consisting of ruxolitinib phosphoric acid salt, ruxolitinib sulfuric acid salt and ruxolitinib maleic acid salt	17th July 2019	REVOKED	37182	3070090	EU/1/12/773		
129/2019	Pearl Therapeutics, Inc. 200 Saginaw Drive Redwood City, CA 94063 / US	RESPIRATORY DELIVERY OF ACTIVE AGENTS	Bevespi Aerosphere - glycopyrronium bromide / formoterol	A combination of glycopyrrolate (including any pharmaceutically acceptable salts, esters, enantiomers or other derivatives thereof) and formoterol (including any pharmaceutically acceptable salts, esters, enantiomers or other derivatives thereof)	31st July 2019	20th December 2033	34528	2435025	EU/1/18/1339		
130/2019	Warner-Lambert Company LLC 235 East 42nd Street New York New York 10017-5755 / US	4-phenylamino-quinazolin-6-yl-amides	Vizimpro - dacomitinib	dacomitinib in the form of a monohydrate	18th October 2019	26th April 2030	2740		EU/1/19/1354		
131/2019	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES	Lorviqua-lorlatinib	Lorlatinib or a pharmaceutically acceptable salt thereof	18th October 2019	8th May 2034	34210	2822953	EU/1/19/1355		
132/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V, Denmark	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab	24/02/2020	24/05/2031	37533	2081595	EU/1/16/1101		
133/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V, Denmark	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab, bortezomib and dexamethasone	24/02/2020	03/05/2032	37533	2081595	EU/1/16/1101		
134/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V, Denmark	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab, lenalidomide and dexamethasone	24/02/2020	03/05/2032	37533	2081595	EU/1/16/1101		
135/2019	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V, Denmark	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex – daratumumab	daratumumab, bortezomib, melphalan and prednisone	24/02/2020	26/09/2032	37533	2081595	EU/1/16/1101		
136/2019	BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, CA 94949 / US	COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE AND METHODS OF USING SAID COMPOSITIONS	Palynziq - pegvaliase	pegvaliase (Palynziq)	12th November 2019	23rd May 2033	33084	2152868	EU/1/19/1362		



137/2019	Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	ANTI-IL-23 ANTIBODIES	Skyrizi - risankizumab	Risankizumab	12th November 2019	30th April 2034	33812	2635601	EU/1/19/1361		
138/2019	Medivation Technologies LLC 525 Market Street, 36th Floor San Francisco, CA 94105 U.S.A.	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Talzenna-talazoparib		14th January 2020	24th June 2034	34614	2767537	EU/1/19/1377		
139/2019	Xencor, Inc. 111 W. Lemon Avenue Monrovia CA 91016 United States of America	Fc variants with altered binding to FcRn	Ultomiris - Ravulizumab	Ultomiris - Ravulizumab	14th January 2020	22nd December 2033	37868	2808343	EU/1/19/1371		
140/2019	Xencor, Inc. 111 W. Lemon Avenue Monrovia CA 91016 United States of America	FC VARIANTS WITH ALTERED BINDING TO FCRN	Ultomiris - Ravulizumab	Ultomiris - Ravulizumab	14th January 2020	22nd December 2033	32529	2235059	EU/1/19/1371		
141/2020	Astellas Pharma Inc. 5-1, Nihonbashi-Honcho 2- chome Chuo-ku Tokyo 103-8411 / JP  Kotobuki Pharmaceutical Co., Ltd. 6351, Oaza Sakaki Sakaki-machi Hanishina-gun, Nagano 389- 0697 / JP	DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND	Xospata-gilteritinib	gilteritinib or a salt thereof	12th May 2020	28th October 2034	33331	2428508	EU/1/19/1399		
142/2020	AbbVie Inc. 1 North Waukegan Road North Chicago, IL 60064 United States of America	NOVEL TRICYCLIC COMPOUNDS	Rinvoq - upadacitinib	upadacitinib	12th May 2020	18th December 2034	34901	2506716	EU/1/19/1404		
143/2020	Array Biopharma, Inc. 3200 Walnut Street Boulder, CO 80301 / US	PYRAZOLO[1,5-]PYRIMIDINE COMPOUND AS TRK KINASE INHIBITOR	VITRAKVI - larotrectinib	Larotrectinib and/or pharmaceutically acceptable salts thereof, particularly larotrectinib sulfate including larotrectinib hydrogen sulfate	12th May 2020	23rd September 2035	36251	3106463	EU/1/19/1385		

144/2020	Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US  COLD SPRING HARBOR LABORATORY Box 100, One Bungtown Road Cold Spring Harbor, NY 11724 / US	COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT	Spinraza - nusinersen	Nusinersen or salts thereof	12th May 2020	1st June 2032	38320	3449926	EU/1/17/1188		
145/2020	AstraZeneca AB 151 85 Södertälje / SE  AstraZeneca UK Limited 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA / GB	BILAYER TABLET FORMULATIONS	Qtrilmet - metformin hydrochloride / saxagliptin / dapagliflozin	Metformin or a pharmaceutically acceptable salt thereof; saxagliptin or a pharmaceutically acceptable salt thereof; dapagliflozin or a pharmaceutically acceptable solvate thereof	9th June 2020	13th November 2034	36392	2498758	EU/1/19/1401		
146/2020	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS	Symtuza - Darunavir ethanolate / cobistat / emtricitabine / tenofovir alafenamide fumarate	Cobicistat or a pharmaceutically acceptable salt or solvate thereof, darunavir or a pharmaceutically acceptable salt or solvate of, in particular darunavir ethanolate, and emtricitabine or a pharmaceutically acceptable salt or solvate thereof	16th June 2020	25th September 2032	38094	3150586	EU/1/17/1225		
147/2020	Rigel Pharmaceuticals, Inc. 1180 Veterans Boulevard South San Francisco, CA 94080 / US	NEW (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL FORMULATIONS	fostamatinib	Tavlesse - fostamatinib	23rd June 2020	13th January 2035	37257	2736487	EU/1/19/1405		
148/2020	Recordati AG Lindenstrasse 8, 6340 Baar / CH	USE OF AN ADRENAL HORMONE-MODIFYING AGENT	Isturisa	Osilodrostat or a pharmaceutically acceptable salt thereof, including osilodrostat dihydrogen phosphate.	14th September 2020	13th January 2035	36588	2523731	EU/1/19/1407		
149/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST	Mayzent	Siponimod	14th September 2020	21st December 2034	33114	2379069	EU/1/19/1414		
150/2020	Helsinn Healthcare SA Via Pian Scaiolo 9 6912 Lugano-Pazzallo / CH	SUBSTITUTED 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK-1 RECEPTOR RELATED DISEASES.	Akynzeo	'fosnetupitant and its pharmaceutically acceptable salts'	14th September 2020	19th March 2035	33931	2785706	EU/1/15/1001		

151/2020	Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE	CICLESONIDE FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES	Aservo EquiHaler - ciclesonide	Ciclesonide or a pharmaceutically acceptable salt thereof	14th September 2020	30th January 2035	36403	2934479	EU/2/19/249		
152/2020	AstraZeneca AB 151 85 Södertälje / SE	PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE	Qtern – saxagliptin / dapagliflozin	Saxagliptin and dapagliflozin	14th September 2020	19th July 2031	38379	2139494	EU/1/16/1108		
153/2020	Orion Corporation Orionintie 1 02200 Espoo / FI	ANDROGEN RECEPTOR MODULATING COMPOUNDS	NUBEQA - darolutamide	darolutamide	14th September 2020	30th March 2035	31955	2493858	EU/1/20/1432		
154/2020	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V, Denmark	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex - daratumumab	daratumumab, bortezomib, thalidomide and dexamethasone	14th September 2020	26th September 2032	37533	2081595	EU/1/16/1101		
155/2020	Melinta Therapeutics, Inc. 44 Whippany Road Suite 280 Morristown, NJ 07960 / US	CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Vabomere – meropenem/vaborbactam	a combination of vaborbactam, and/or a salt and/or hydrate thereof, and meropenem, and/or a salt and/or hydrate thereof, in particular meropenem trihydrate	22nd September 2020	22nd November 2033	38648	3412676	EU/1/18/1334		
156/2020	Melinta Therapeutics, Inc. 44 Whippany Road Suite 280 Morristown, NJ 07960 / US	CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Vabomere – meropenem/vaborbactam	vaborbactam, and/or a salt and/or hydrate thereof	22nd September 2020	22nd November 2033	38648	3412676	EU/1/18/1334		
157/2020	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 / US	Anti-CD79b antibodies and immunoconjugates and methods of use	Polivy – polatuzumab Vedotin	Polatuzumab vedotin	14th September 2020	15th July 2033	32584	2474557	EU/1/19/1388		
158/2020	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	Beta-lactamase Inhibitors	Recarbrio – imipenem / cilastatin / relebactam	relebactam, optionally in the form of the monohydrate, imipenem and cilastatin, optionally in the form of the sodium salt	22nd September 2020	15th January 2034	32252	2666774	EU/1/19/1420		
159/2020	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	Beta-lactamase Inhibitors	Recarbrio – imipenem / cilastatin / relebactam	relebactam, optionally in the form of the monohydrate, and imipenem	22nd September 2020	15th January 2034	32252	2666774	EU/1/19/1420		
160/2020	Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, NJ 07065 / US	BETA-LACTAMASE INHIBITORS	Recarbrio – imipenem / cilastatin / relebactam	relebactam or a monohydrate thereof	22nd September 2020	15th January 2034	31533	2231667	EU/1/19/1420		
161/2020	NOVARTIS AG Lichtstrasse 35, Basel 4056 / Switzerland	STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF	Beovu - brolocizumab	brolocizumab	22nd September 2020	25th June 2034	34642	2307454	EU/1/19/1417		

162/2020	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	BENZIMIDAZOLE DERIVATIVES	Daurismo - glasdegib	glasdegib, optionally in the form of a pharmaceutically acceptable salt, including the maleate salt	22nd September 2020	16th June 2033	34062	2170860	EU/1/20/1451		
163/2020	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID	Orkambi – Lumacaftor / Ivacaftor	A combination of (a) 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and (b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof	22nd September 2020	24th November 2030	38807	3170818	EU/1/15/1059		
164/2020	The Scripps Research Institute 10550 North Torrey Pines Road La Jolla, CA 92037 / US	NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS	Zeposia - ozanimod	Ozanimod or a pharmaceutically acceptable salt thereof, in particular ozanimod hydrochloride	22nd September 2020	14th May 2034	38808	2913326	EU/1/20/1442		
165/2020	Receptos LLC 430 East 29th Street, 14th Floor, New York, NY 10016 / US	SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS	Zeposia - ozanimod	Ozanimod or a pharmaceutically acceptable salt thereof, in particular ozanimod hydrochloride	22nd September 2020	25th May 2035	36355	2498610	EU/1/20/1442		
166/2020	Anylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 / US  Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place New York, NY 10029 / US	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE	Givlaari - givosiran	Givosiran or a pharmaceutically acceptable salt thereof	29th September 2020	04th March 2035	38833	3052628	EU/1/20/1428		
167/2020	Nabriva Therapeutics GmbH Leberstrasse 20 1112 Wien / AT	PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES	Xenleta - lefamulin	Lefamulin, salts and solvates thereof	29th September 2020	19th March 2033	30511	2137143	EU/1/20/1457		
168/2020	Astellas Pharma Inc. 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo 103-8411 / JP	2-ACYLAMINOTHIAZOLE COMPOUND CRYSTALS	Doptelet - avatrombopag	Avatrombopag maleate (1-(3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexyl piperazin-1-yl)thiazol-2-yl] carbamoyl] pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt)	3rd November 2020	24th June 2034	38705	3246325	EU/1/19/1373		
169/2020	Chiesi Farmaceutici S.p.A. Via Palermo 26/A 43122 Parma / IT	PROCESS FOR PRODUCTION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALPHA-MANNOSIDASE	Lamzede - velmanase alfa	alpha-mannosidase, in particular velmanase alfa	3rd November 2020	27th March 2033	38945	3281636	EU/1/17/1258		

170/2020	Shionogi & Co., Ltd. 1-8, Doshomachi 3-chome Chuo-ku Osaka-shi Osaka 541-0045 / JP	CEPHALOSPORIN HAVING CATECHOL GROUP	Fetroja - cefiderocol	Cefiderocol, optionally in the form of a pharmaceutically acceptable salt or solvate	24th November 2020	27th October 2034	33887	2960244	EU/1/20/1434		
171/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	1-((5-HETEROARYLTHIAZOL-2- YL)AMINOCARBONYL)PYRROLIDINE-2- CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES	Piqray - alpelisib	Alpelisib or a pharmaceutically acceptable salt thereof	24th November 2020	08th September 2034	33793	2331537	EU/1/20/1455		
172/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST	Zeposia - ozanimod	Ozanimod	21st December 2020	21st December 2034	38057	3409274	EU/1/20/1442		
173/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS	Aectura Breezhaler - indacaterol / mometasone furoate Bemrist Breezhaler - indacaterol / mometasone furoate	indacaterol acetate or indacaterol xinafoate in combination with mometasone furoate	21st December 2020	2nd July 2032	30926	2044025	EU/1/20/1438 - EU/1/20/1441		
174/2020	SANOFI 54, rue La Boétie 75008 Paris / FR	NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER	Sarclisa - isatuximab	isatuximab	29th December 2020	16th October 2032	37643	2076540	EU/1/20/1435		
175/2020	SANOFI 54, rue La Boétie 75008 Paris / FR  The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US	COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE	Sarclisa - isatuximab	isatuximab	5th January 2021	3rd June 2035	37856	2928495	EU/1/20/1435		
176/2020	Novartis AG Lichtstrasse 35 4056 Basel / CH	QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS	Energair Breezhaler - indacaterol / glycopyrronium / mometasone furoate Zimbus Breezhaler - indacaterol / glycopyrronium / mometasone furoate	Indacaterol acetate or indacaterol xinafoate, preferably indacaterol acetate, in combination with mometasone furoate and glycopyrronium	12th January 2021	2nd July 2032	30926	2044025	EU/1/20/1438 - EU/1/20/1440		
177/2020	Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard, Boston, Massachusetts 02210 / US	ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME	Ondexxya - andexanet alfa	Andexanet Alfa	12th January 2021	26th September 2033	38778	3078743	EU/1/18/1345		
178/2020	Acceleron Pharma Inc. 128 Sidney Street Cambridge, MA 02139 / US	GDF TRAPS FOR USE TO TREAT ANEMIA	Reblozyl - luspatercept	Luspatercept in all its forms protected by the basic patent	12th January 2021	13th August 2034	37321	2340031	EU/1/20/1452		

179/2020	GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US	1' -substituted carba-nucleoside analogs for antiviral treatment	Veklury - remdesivir	Remdesivir or a pharmaceutically acceptable salt thereof	12th January 2021	22nd April 2034	35616	2937350	EU/1/20/1459		
180/2020	Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Bavencio - avelumab	avelumab	8th February 2021	20th September 2032	39064	2785375	EU/1/17/1214		
181/2021	Melinta Subsidiary Corp. 44 Whippany Road, Suite 280 Morristown, NJ 07960 / US	PROCESS FOR MAKING QUINOLONE COMPOUNDS	Quofenix - delafloxacin	delafloxacin or a salt or ester thereof, including delafloxacin meglumine	8th March 2021	23rd September 2034	39088	3214083	EU/1/19/1393		
182/2021	SHIONOGI & CO., LTD 1-8, Doshomachi 3-chome Chuo-ku Osaka-shi Osaka 541-0045 / JP	ANTI-INFLUENZA POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF	Xofluza - baloxavir marboxil	baloxavir marboxil or a pharmaceutically acceptable salt thereof	1st June 2021	8th January 2036	39649	3428170	EU/1/20/1500		
183/2021	Blueprint Medicines Corporation 45 Sidney Street Cambridge, MA 02139 / US	COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT	AYVAKYT - avapritinib	Avapritinib and pharmaceutically acceptable salts thereof	12th April 2021	25th September 2035	36548	3057969	EU/1/20/1473		
184/2021	Galapagos N.V. Generaal de Wittelaan L11 A3 2800 Mechelen / BE	5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2- YL CARBOXAMIDES AS JAK INHIBITORS	Jyseleca - filgotinib	Filgotinib or a salt thereof	12th April 2021	25th June 2035	34666	2445911	EU/1/20/1480		
185/2021	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem / NL	4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK-INHIBITORS	Calquence - acalabrutinib	Acalabrutinib or a pharmaceutically acceptable salt thereof	1st June 2021	6th November 2035	37261	2734522	EU/1/20/1479		
186/2021	Novartis AG Lichtstrasse 35 4056 Basel / CH  Oklahoma Medical Research Foundation 825 N.E. 13th Street Oklahoma City, OK 73104 / US	Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases	Adakveo - crizanlizumab	crizanlizumab	1st June 2021	30th November 2032	36383	2662091	EU/1/20/1476		
187/2021	Scott & White Memorial Hospital 2401 South 31st Street Temple, TX 76508 / US	METHODS AND COMPOSITIONS BASED ON DIPHThERIA TOXIN-INTERLEUKIN-3 CONJUGATES	ELZONRIS - tagraxofusp	tagraxofusp	1st June 2021	7th September 2032	38869	3207941	EU/1/20/1504		

188/2021	Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US	SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE	Symkevi - tezacaftor/ivacaftor	A combination of (a) (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide or a pharmaceutically acceptable salt thereof and (b) N-(5-hydroxy-2,4-ditert-but	14th June 2021	6th November 2033	39448	2826776	EU/1/18/1306		
189/2021	Pearl Therapeutics, Inc. 200 Saginaw Drive Redwood City, CA 94063 / US	COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS	TRIXEO AEROSPHERE - Formoterol / glycopyrronium bromide / budesonide	A combination of formoterol (including any pharmaceutically acceptable salts, esters, solvates or enantiomers thereof), glycopyrrolate (including any pharmaceutically acceptable salts, esters, solvates or enantiomers thereof) and budesonide (including any	22nd June 2021	28th May 2035	34511	2435024	EU/1/20/1498		
190/2021	Alnylam Pharmaceuticals, Inc. 675 West Kendall Street Henri A. Termeer Square, Cambridge, MA 02142 / US	PCSK9 IRNA COMPOSITIONS AND METHODS OF USE THEREOF	Leqvio - inclisiran	inclisiran	19th July 2021	10th December 2035	35301	2929031	EU/1/20/1494		
191/2021	Boehringer Ingelheim Animal Health USA Inc. 3239 Satellite Boulevard, Bldg. 500 Duluth, GA 30096 / US	PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHOD AND USES THEREOF	NexGard Combo - esafoxolaner / eprinomectin / praziquantel	A combination of Afoxolaner, Eprinomectin and Praziquantel	26th July 2021	7th January 2036	39159	3172964	EU/2/20/267		
192/2021	Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP	ANTI-HER2 ANTIBODY-DRUG CONJUGATE	Enhertu - trastuzumab deruxtecan	trastuzumab deruxtecan	26th July 2021	20th January 2036	36748	3101032	EU/1/20/1508		
193/2021	REGENERON PHARMACEUTICALS, INC. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 / US	VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION	Eylea - aflibercept ZALTRAP - aflibercept	Aflibercept	26th July 2021	26th November 2027	39323	2944306	EU/1/12/797; EU/1/12/814	PEC 13/2023	26/05/2028
194/2021	Array Biopharma, Inc. 3200 Walnut Street Boulder, CO 80301 / US	SOLID DISPERSION	TUKYSA - tucatinib	tucatinib	23rd August 2021	12th February 2036	35009	2765990	EU/1/20/1526		

195/2021	Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington, Massachusetts 02421 / US	METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA	Oxlumo - lumasiran	lumasiran	27th September 2021	23rd November 2035	40103	3581654	EU/1/20/1496		
196/2021	Incyte Holdings Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 / US	SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS	Pemazyre - pemigatinib	pemigatinib or a pharmaceutically acceptable salt thereof	11th October 2021	29th March 2036	34608	2861595	EU/1/21/1535		
197/2021	Amarin Pharmaceuticals Ireland Limited 2 Pembroke House Upper Pembroke Street 28-32 Dublin 2 / IE	COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY	Vazkepa - icosapent ethyl	icosapent ethyl	11th October 2021	15th June 2035	35466	2443246	EU/1/21/1524		
198/2021	Novartis AG Lichtstrasse 35 4056 Basel / CH	ANTI-CD20 ANTIBODY FORMULATIONS	Kesimpta - ofatumumab	ofatumumab	18th October 2021	3rd July 2033	34756	2170388	EU/1/21/1532		
199/2021	Adverio Pharma GmbH Kaiser-Wilhelm-Allee 1 Leverkusen 51373 / DE	SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF	Verquvo - vericiguat	vericiguat	18th October 2021	24th May 2036	33377	2576547	EU/1/21/1561		
200/2021	AnaptysBio, Inc. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 / US	ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 (PD-1)	JEMPERLI - dostarlimab	dostarlimab	18th October 2021	22nd April 2036	39638	2992017	EU/1/21/1538		
201/2021	Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US	ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF	Evkeeza - evinacumab	evinacumab	11th October 2021	18th June 2036	37137	2721065	EU/1/21/1551		
202/2021	Karyopharm Therapeutics, Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459 / US	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	NEXPOVIO - selinexor	selinexor	18th October 2021	29th March 2036	35920	2736887	EU/1/21/1537		
203/2021	CEV, S.A., Parque Tecnológico de Cantanhede Núcleo 04 Lote 2, 3060-197 Cantanhede / PT	USE OF CHELATING AGENT AND PEPTIDE ANTIMICROBIAL COMPOUNDS	Aqueous extract from the germinated seeds of sweet Lupinus albus	BLAD protein	1st November 2021	6th April 2036	33923	2627177	(EU) 2021/567		
204/2021	Biocryst Pharmaceuticals, Inc., 4505 Emperor Blvd., Durham, North Carolina 27703 / US	TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS	Orladeyo - berotralstat	Berotralstat and pharmaceutically acceptable salts thereof	1st November 2021	4th May 2036	39507	3113772	EU/1/21/1544		
205/2021	Aragon Pharmaceuticals, Inc. 10990 Wilshire Blvd. Suite 300 Los Angeles, CA 90024 / US  Sloan Kettering Institute For Cancer Research 1275 York Avenue New York, NY 10065 / US	CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR	Erleada - apalutamide	Apalutamide	22nd November 2021	16th January 2034	39863	3533792	EU/1/18/1342		



206/2021	AstraZeneca AB Sodertälje SE-151 85 / SE  Array Biopharma, Inc. 3200 Walnut Street Boulder, CO 80301 / US	NOVEL HYDROGEN SULFATE SALT	Koselugo - selumetinib	Selumetinib (including any pharmaceutically acceptable salts [particularly hydrogen sulfate], esters, solvates or enantiomers thereof)	22nd November 2021	19th December 2031	3995		EU/1/21/1552		
207/2021	Albireo AB Arvid Wallgrens Backe 20 413 46 Göteborg / SE	IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES	Bylvay - odeixibat	odeixibat	6th December 2021	19th July 2036	39029	3400944	EU/1/21/1566		
208/2021	Millenium Pharmaceuticals, Inc. 40 Landsdowne Street, Cambridge, MA 02139 / US	ADENINE DERIVATIVE AS PI3K INHIBITOR	Copiktra - Duvelisib	duvelisib	6th December 2021	15th July 2035	32398	2456444	EU/1/21/1542		
209/2021	Infinity Pharmaceuticals, Inc. 1100 Massachusetts Avenue, 4th Floor, Cambridge MA 02138 / US	TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS	Copiktra - Duvelisib	duvelisib	6th December 2021	21st May 203	36411	2914296	EU/1/21/1542		
210/2021	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V, Denmark	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex - daratumumab	daratumumab, cyclophosphamide, bortezomib and dexamethasone	17th January 2022	26th September 2032	37533	2081595	EU/1/16/1101		
211/2021	Genmab A/S Kalvebod Brygge 43, 1560 Copenhagen V, Denmark	ANTI-CD38 PLUS CORTICOSTEROIDS PLUS A NON-CORTICOSTEROID CHEMOTHERAPEUTIC FOR TREATING TUMORS	Darzalex - daratumumab	daratumumab, pomalidomide, and dexamethasone	17th January 2022	26th September 2032	37533	2081595	EU/1/16/1101/001 - 002		
212/2022	UCB Biopharma SPRL Allée de la Recherche 60 1070 Brussels / BE	ANTIBODY BINDING IL-17A AND IL-17F	Bimzelx - bimekizumab	bimekizumab	14th February 2022	23rd August 2036	35352	2663577	EU/1/21/1575		
213/2022	Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US	PYRROLO [2,3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS KINASES (JAK)	Cibinqo - abrocitinib	Abrocitinib, or a pharmaceutically acceptable salt thereof	28th February 2022	10th December 2036	34979	2958921	EU/1/21/1593		
214/2022	Beigene, Ltd. 94 Solaris Avenue PO Box 1348 George Town Grand Cayman KY1-1108 / KY	FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS	Brukinsa - zanubrutinib	Zanubrutinib or a pharmaceutically acceptable salt thereof	7th March 2022	23rd November 2036	34433	2989106	EU/1/21/1576		
215/2022	Xencor, Inc. 111 W. Lemon Avenue Monrovia, CA 91016 / US	OPTIMIZED ANTIBODIES THAT TARGET CD19	Minjuvi - tafasitamab	tafasitamab	14th March 2022	14th August 2032	31266	2383297	EU/1/21/1570		

216/2022	Development Les Templiers 2400 Route des Colles, 06410 Biot, France	NOVEL LIGANDS THAT MODULATE RAR RECEPTORS, AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS	Aklief 50 microgram/g cream	Trifarotene, optionally in the form of a pharmaceutically acceptable salt.	4th April 2022	23rd December 2030	3207	0	MA117/01501		
217/2022	Alkermes Pharma Ireland Limited Connaught House 1 Burlington Road Dublin 4 / IE	PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES	Vumerity - diroximel fumarate	Vumerity (diroximel fumarate)	18th April 2022	16th November 2036	36774	2970101	EU/1/21/1585		
218/2022	ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S Tuborg Boulevard 12 2900 Hellerup / DK	NOVEL POLYMERIC HGH PRODRUGS	Lonapegsomatropin Ascendis Pharma - Lonapegsomatropin	Lonapegsomatropin Ascendis Pharma	16th May 2022	17th January 2037	40440	3653227	EU/1/21/1607		
219/2022	Deciphera Pharmaceuticals, LLC 643 Massachusetts, Suite 200 Lawrence, Kansas 66044 / US	DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES	QINLOCK - ripretinib	Ripretinib or a pharmaceutical acceptable salt thereof	16th May 2022	24th November 2036	38512	3366293	EU/1/21/1569		
220/2022	Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50, 40789 Monheim am Rhein / DE	SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF	Kerendia - finerenone	Finerenone and its salts, solvates and solvates of the salts thereof	30th May 2022	19th February 2033	32564	2132206	EU/1/21/1616		
221/2022	Alnylam Pharmaceuticals, Inc. 675 West Kendall Street Henri. A. Termeer Square Cambridge, MA 02142 / US	COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION	Oxlumo - lumasiran	Lumasiran, optionally in the form of a salt	13th June 2022	23rd November 2035	40971	3204015	EU/1/20/1496		
222/2022	AstraZeneca AB 151 85 Södertälje / SE	ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY	Saphnelo - anifrolumab	anifrolumab	6th June 2022	6th February 2034	34237	2250279	EU/1/21/1623		
223/2022	Estetra SRL Rue Saint-Georges 5-7 4000 Liège / BE	ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT	Lydisilka - drospirenone / estetrol	drospirenone in combination with estetrol	27th June 2022	20th May 2036	41028	3701944	EU/1/21/1548		

224/2022	Janssen Biotech, Inc. 800/850 Ridgeview Drive Horsham, PA 19044 / US	BISPECIFIC EGFR/C-MET ANTIBODIES	Rybrevant - amivantamab	Rybrevant - amivantamab	27th June 2022	10th December 2036	36378	2922872	EU/1/21/1594		
225/2022	Apellis Pharmaceuticals, Inc. 100 5th Avenue Waltham, MA 02451 / US	LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS	ASPAVELI - Pegcetacoplan	Pegcetacoplan	27th June 2022	14th December 2036	40312	3660033	EU/1/21/1595		
226/2022	Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE	PYRIDAZINONE DERIVATES	Tepmetko - tepotinib	tepotinib and pharmaceutically usable solvates, salts, tautomers and stereoisomers thereof	18th July 2022	29th April 2033	32170	2164843	EU/1/21/1596		
227/2022	Fibrogen, Inc. 409 Illinois Street San Francisco, CA 94158 / US	CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR	Evrenzo - roxadustat	Roxadustat	18th July 2022	19th August 2036	41057	3470397	EU/1/21/1574		
228/2022	H. Lundbeck A/S Ottiliavej 9 2500 Valby / DK	ANTI-CGRP COMPOSITIONS AND USE THEREOF	Vyepti - eptinezumab	eptinezumab	18th July 2022	25th January 2037	40972	3495392	EU/1/21/1599		
229/2022	Actelion Pharmaceuticals Ltd Gewerbstrasse 16 4123 Allschwil / CH	DOSING REGIMEN FOR PONESIMOD, A SELECTIVE S1P1 RECEPTOR AGONIST	Ponvory - ponesimod	Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one) or pharmaceutically acceptable salts thereof	1st August 2022	21st May 2036	41142	3256125	EU/1/21/1550		
230/2022	Global Blood Therapeutics, Inc. 181 Oyster Point Blvd., South San Francisco, CA 94080 / US	SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION	Oxbryta - voxelotor	Voxelotor or a tautomer or pharmaceutically acceptable salt thereof	22nd August 2022	15th February 2037	35035	2797416	EU/1/21/1622		
231/2022	Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US	CGRP receptor antagonists	Vydura - rimegepant	Rimegepant or a pharmaceutically acceptable salt thereof	5th September 2022	13th October 2035	32008	2488512	EU/1/22/1645		

232/2022	PharmaEssentia Corp. 13F, No. 3. Park St. Nangang District Taipei 115 / TW	PROTEIN-POLYMER CONJUGATES	Besremi - ropeginterferon alfa-2b	ropeginterferon alfa-2b	26th September 2022	15th August 2033	41177	2205281	EU/1/18/1352		
233/2022	Agensys, Inc. 1 Astellas Way Northbrook, IL 60062 / US  Seagen Inc. 21823 30th Drive, S.E. Bothell, WA 98021 / US	ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS	Padcev - enfortumab vedotin	enfortumab vedotin	17th October 2022	29th September 2036	36108	2621526	EU/1/21/1615		
234/2022	Viela Bio, Inc. One MedImmune Way 5th Floor, Suite Area 2 Gaithersburg, MD 20878 / US	HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF TUMORS, TRANSPLANTATION AND AUTOIMMUNE DISEASES	Uplizna - Inebilizumab	Inebilizumab	8th November 2022	7th September 2032	30706	2066349	EU/1/21/1602		
235/2022	Novartis AG Lichtstrasse 35 4056 Basel / CH	BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1	Scemblix - asciminib	Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride	14th November 2022	26th August 2037	35763	2861579	EU/1/22/1670		
236/2022	Genethon 1 bis rue de l'Internationale 91000 Evry / FR  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE 3, rue Michel Ange 75016 Paris / FR	WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL INJECTION OF AAV VECTORS	Zolgensma - onasemnogene abeparvovec	onasemnogene abeparvovec	5th December 2022	3rd October 2033	41451	3505635	EU/1/20/1443		
237/2022	AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320 / US	ANTIGEN BINDING PROTEINS CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN	Tezspire - tezepelumab	tezepelumab	2nd January 2023	9th September 2033	33791	2205635	EU/1/22/1677		
238/2022	Incyte Holdings Corporation 1801 Augustine Cut-Off, Wilmington, DE 19803 / US	IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS	Tabrecta - capmatinib	capmatinib or a pharmaceutically acceptable salt thereof	2nd January 2023	19th November 2032	31047	2099447	EU/1/22/1650		

239/2023	CoLucid Pharmaceuticals, Inc. 2530 Meridian Parkway, Suite 300 Durham, NC 27713 / US	2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE FOR THE TREATMENT OF MIGRAINE VIA THE ORAL OR INTRAVENOUS ROUTE	RAYVOW - lasmiditan	Lasmiditan or a pharmaceutically acceptable salt thereof	23rd January 2023	2nd April 2035	35629	2413933	EU/1/21/1587		
240/2023	BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, CA 94949 / US  University College London Gower Street London WC1E 6BT / GB  St. Jude Children's Research Hospital 262 Danny Thomas Place Memphis, TN 38105-3678 / US	AAV VECTORS COMPRISING A GENE ENCODING FACTOR VIII	valoctocogene roxaparovec	valoctocogene roxaparovec in all forms as protected by the basic patent	30th January 2023	25th August 2037	39930	3044231	EU/1/22/1168		
241/2023	Oncopeptides AB Västra Trädgårdsgatan 15 111 53 Stockholm / SE	LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES	Pepaxti - melphalan flufenamide	Melphalan flufenamide hydrochloride	30th January 2023	25th April 2037	35663	2701720	EU/1/22/1669/001		
242/2023	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 / US	AMIDE COMPOUNDS FOR THE TREATMENT OF HIV	Sunlenca - lenacapavir	Lenacapavir or a pharmaceutically acceptable salt thereof, in particular lenacapavir sodium	30th January 2023	19th August 2037	36339	2961742	EU/1/22/1671		
243/2023	Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US	Compositions and uses for treating Multiple Sclerosis	Tecfidera - Dimethyl fumarate	Tecfidera (dimethyl fumarate)			41688	2653873	EU/1/13/837		
244/2023	Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US	OPTIMIZATION OF HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF	Opdualag - nivolumab/relatlimab	relatlimab	13th February 2023	16th September 2037	34738	2867258	EU/1/22/1679	PEC 16/2023	16/03/2038
245/2023	Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US	GIP AND GLP-1 CO-AGONIST COMPOUNDS	Mounjaro - tirzepatide	tirzepatide and pharmaceutically acceptable salts thereof	13th February 2023	19th September 2037	37383	3242887	EU/1/22/1685		
246/2023	Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US	TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES	Amvuttra - vutrisiran	vutrisiran	27th February 2023	16th September 2037	39937	3329002	EU/1/22/1681		

247/2023	F. Hoffmann-La Roche AG Grenzacherstrasse 124, CH-4070, Basel / CH	BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES	Vabysmo - Faricimab	Faricimab	27th February 2023	16th September 2037	41062	3495387	EU/1/22/1683		
248/2023	Immunomedics Inc. c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 / US	IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE	Trodely - sacituzumab govitecan	sacituzumab govitecan	6th March 2023	2nd December 2034	41617	3912643	EU/1/21/1592		
249/2023	Janssen Biotech, Inc. 800/850 Ridgeview Drive, Horsham PA, 19044 / US	ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES THEREOF	TECVAYLI - teclistamab	teclistamab	13th March 2023	24th August 2037	38803	3337824	EU/1/22/1675		
250/2023	Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge, MA 02139 / US	QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY	Pyrukynd - mitapivat	Mitapivat or a pharmaceutically acceptable salt thereof, in particular mitapivat sulfate	15th May 2023	29th June 2035	33811	2448582	EU/1/22/1662		
251/2023	MEDIMMUNE LIMITED Milstein Building, Granta Park, Cambridge, CB21, 6GH / UK	RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF	Beyfortus - nirsevimab	nirsevimab	15th May 2023	3rd November 2037	39256	3094353	EU/1/22/1689		

As on 31 May 2023